Innovation Theater 2
Supported By: Avalyn Pharma

---

Program Description

Join us for an insightful Innovation Mini-Theater exploring the evolving landscape of pulmonary fibrosis (PF) treatment, with a focus on the innovative potential of AP02, our novel inhaled nintedanib formulation. This program will delve into the critical unmet needs in PF management and showcase the groundbreaking work being conducted by Avalyn Pharma to address these challenges.

Avalyn Pharma is at the forefront of developing targeted inhaled antifibrotic therapies, aiming to revolutionize the treatment paradigm for patients living with PF. This symposium will provide a comprehensive overview of Avalyn’s pipeline, highlighting its commitment to scientific innovation and patient-centric solutions. We will begin by exploring the foundational principles guiding Avalyn’s research, emphasizing the strategic advantage of inhaled drug delivery in maximizing lung exposure while minimizing systemic toxicity.

The core of this symposium will center on AP02, Avalyn’s novel inhaled nintedanib formulation. Nintedanib, a well-established oral antifibrotic, has demonstrated efficacy in slowing disease progression in PF. However, its systemic administration is often associated with significant side effects, limiting its tolerability and optimal dosing. AP02 aims to overcome these limitations by delivering nintedanib directly to the lungs, the primary site of disease activity.

Attendees will gain access to exclusive insights into the results of Avalyn’s Phase 1 clinical studies, which evaluated both single and repeated doses of AP02. These studies have provided critical data on the safety, tolerability, and pharmacokinetic profile of AP02, demonstrating its potential to achieve clinically meaningful lung exposures, while dramatically reducing systemic exposure. We will review the key findings from these studies, including the observed safety profile. This symposium will provide a platform for engaging discussions on the future of PF treatment, exploring the potential of AP02 to transform patient care. It is designed for pulmonologists, respiratory therapists, clinical researchers, and other healthcare professionals seeking to stay abreast of the latest advancements in PF management. Join us as we explore how AP02 is poised to breathe new life into the treatment of pulmonary fibrosis.

This program was developed by Avalyn Pharma and is neither sponsored by nor endorsed by ATS and does not offer CME/CE credit.

Speakers

Presenter: Joyce Lee, MD, MAS, ATSF
University of Colorado
Division of Pulmonary Sciences and Critical Care
Professor, Medicine; Director of Interstitial Lung Disease Program
Denver, Colorado

Presenter: Howard Lazarus, MD, FCCP
Chief Medical Officer
Avalyn Pharma